Johnson LG - Search Results

1

RS 23597-190: a potent and selective 5-HT4 receptor antagonist.

Eglen RM, Bley K, Bonhaus DW, Clark RD, Hegde SS, Johnson LG, Leung E, Wong EH. Eglen RM, et al. Among authors: johnson lg. Br J Pharmacol. 1993 Sep;110(1):119-26. doi: 10.1111/j.1476-5381.1993.tb13780.x. Br J Pharmacol. 1993. PMID: 8220871 Free PMC article.

2

RS 39604: a potent, selective and orally active 5-HT4 receptor antagonist.

Hegde SS, Bonhaus DW, Johnson LG, Leung E, Clark RD, Eglen RM. Hegde SS, et al. Among authors: johnson lg. Br J Pharmacol. 1995 Jul;115(6):1087-95. doi: 10.1111/j.1476-5381.1995.tb15922.x. Br J Pharmacol. 1995. PMID: 7582507 Free PMC article.

3

Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.

Eglen RM, Lee CH, Smith WL, Johnson LG, Clark R, Whiting RL, Hegde SS. Eglen RM, et al. Among authors: johnson lg. Br J Pharmacol. 1995 Feb;114(4):860-6. doi: 10.1111/j.1476-5381.1995.tb13283.x. Br J Pharmacol. 1995. PMID: 7773547 Free PMC article.

4

(R) and (S) RS 56532: mixed 5-HT3 and 5-HT4 receptor ligands with opposing enantiomeric selectivity.

Eglen RM, Bonhaus DW, Clark RD, Johnson LG, Lee CH, Leung E, Smith WL, Wong EH, Whiting RL. Eglen RM, et al. Among authors: johnson lg. Neuropharmacology. 1994 Mar-Apr;33(3-4):515-26. doi: 10.1016/0028-3908(94)90083-3. Neuropharmacology. 1994. PMID: 7984291

5

RS 42358-197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo.

Eglen RM, Lee CH, Smith WL, Johnson LG, Whiting RL, Hegde SS. Eglen RM, et al. Among authors: johnson lg. J Pharmacol Exp Ther. 1993 Aug;266(2):535-43. J Pharmacol Exp Ther. 1993. PMID: 8355189

6

The action of SDZ 205,557 at 5-hydroxytryptamine (5-HT3 and 5-HT4) receptors.

Eglen RM, Alvarez R, Johnson LG, Leung E, Wong EH. Eglen RM, et al. Among authors: johnson lg. Br J Pharmacol. 1993 Feb;108(2):376-82. doi: 10.1111/j.1476-5381.1993.tb12812.x. Br J Pharmacol. 1993. PMID: 8448587 Free PMC article.

7

Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo.

Eglen RM, Bonhaus DW, Johnson LG, Leung E, Clark RD. Eglen RM, et al. Among authors: johnson lg. Br J Pharmacol. 1995 Aug;115(8):1387-92. doi: 10.1111/j.1476-5381.1995.tb16628.x. Br J Pharmacol. 1995. PMID: 8564196 Free PMC article.

8

Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase.

Stanley WC, Li B, Bonhaus DW, Johnson LG, Lee K, Porter S, Walker K, Martinez G, Eglen RM, Whiting RL, Hegde SS. Stanley WC, et al. Among authors: johnson lg. Br J Pharmacol. 1997 Aug;121(8):1803-9. doi: 10.1038/sj.bjp.0701315. Br J Pharmacol. 1997. PMID: 9283721 Free PMC article.

9

Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine beta-hydroxylase inhibitor.

Stanley WC, Lee K, Johnson LG, Whiting RL, Eglen RM, Hegde SS. Stanley WC, et al. Among authors: johnson lg. J Cardiovasc Pharmacol. 1998 Jun;31(6):963-70. doi: 10.1097/00005344-199806000-00023. J Cardiovasc Pharmacol. 1998. PMID: 9641484

10

Effects of enprostil on cardiovascular and respiratory parameters in the dog, and on hematologic parameters in the rat, monkey, and human.

Johnson LG, Bruno JJ, Allely MC, Eglen RM, Chang K, Yang D, Alps BJ, Rosenkranz RP, Strosberg AM. Johnson LG, et al. Arzneimittelforschung. 1989 Nov;39(11):1443-8. Arzneimittelforschung. 1989. PMID: 2515862

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

197 results

Search Page

Filters